Patient agreement to systemic anti-cancer

therapy (SACT)	
. ,	Patient's first name(s):
Hydroxycarbamide	Date of birth:
Hospital/NHS Trust/NHS Board:	NHS number: (or other identifier) Special requirements: (eg other language/other communication method)
Responsible consultant:	
Job title:	
Name of proposed course of treatment (include	de brief explanation if medical term not clear)
how often to take it. Treatment is continued until disease progression, u This medicine used to be called Hydroxyurea. It ma Where will I have treatment?	ay. This may be every day or only on some days, will tell you how much Hydroxycarbamide to take and nacceptable side effects or withdrawal of consent.
Statement of health profession	nal
to be filled in by health professional with appropriate he hospital/Trust/NHS board's consent policy)	
☑ Tick all relevant boxes ☐ I confirm the patient has capacity to give consent.	
I have explained the course of treatment and inten	ded benefit to the patient.
The intended benefits (there are no guarantees al	bout outcome)
☐ To prevent or reduce the risk of thrombosis (blood	clots) and/or bleeding.
To reduce spleen size.	
To control blood counts.	

Patient details

Patient's surname/family name:

To be retained in patient notes Prepared by Pharmacist: Alia Nizam Checked by Pharmacist: Reema Savjani Checked by Consultant: Adam Mead

☐ To control symptoms.

Statement of health professional

Patient identifier/label

You may have one or more of the side effects listed

Common side effects:	Other risks continued
Affecting more than 10 in every 100 (>10%) people	Allergic reactions, thinning of hair or hair loss due to hydroxycarbamide are rare.
Anaemia (due to low red blood cells), bruising or bleeding (due to low platelets), low white blood cells (which may increase your risk of infections).	Although some studies have suggested Hydroxycarbamide increases the risk of disease progression to a form of leukaemia. This has not been proven and most studies do not support a
 Skin ulcers (this is usually on the lower legs and feet), skin changes (inflammation, redness, rashes, darkening, peeling, raised patches, itching). Nail changes (change in colour, thicker or brittle). Feeling sick (nausea), being sick (vomiting), 	causal link. Increased risk of skin cancers. Protect your skin from sun exposure and check your skin for any changes in appearance, new growths or lesions (that may look like a new wart), or change in the size or colour of a mole. Let your haematology team know if you're worried about any
diarrhoea, constipation, tummy pain, indigestion, dark stools.	new/enlarging skin growths or lesions. Cancer and its treatment can increase your risk of
Sore mouth and ulcers, weight loss, tiredness and feeling weak (fatigue), general aches and pain, chills.	developing a blood clot (thrombosis), causing pain, redness and swelling in an arm or leg, breathlessness, chest pain or stroke. Tell your doctor straight away if you have any symptoms.
 Pain when passing urine, changes in kidney function (picked up in blood tests). Gout (pain and inflammation in the joints), most commonly in toes. 	You may notice changes in your memory, concentration, or your ability to think clearly. There can be many causes of this including your treatment, diagnosis, or both.
Occasional side effects: Affecting between 1-10 in every 100 (1-10%) people Effects on the nervous system (headaches, dizziness, fits). Numbness or tingling in hands and feet. Feeling drowsy, feeling confused, hallucinations.	Before treatment, you might have blood tests to check for viruses such as Hepatitis B, Hepatitis C, HIV or more unusual infections. This treatment may weaken your natural defence (immune) system, so infections like this could worsen or become active again if you've had them in the past. You may have medicines to prevent or treat infection. Please make sure you have received all vaccinations recommended for you.
Changes in liver function (picked up in blood tests and monitored).	Some anti-cancer medicines can damage ovaries and sperm. This may lead to infertility and/or early
Other risks:	menopause.
If you have a low white blood cell count, you have an increased risk of getting an infection. If you have a severe infection this can be lifethreatening. Contact your doctor or hospital straight away if; your temperature goes over 37.5°C or over 38°C, or you suddenly feel unwell (even with a normal temperature), depending on the advice given by your chemotherapy team.	 Some anti-cancer medicines may damage the development of a baby in the womb. It is important not to become pregnant during treatment or make someone else pregnant during treatment and for several months after. Use effective contraception throughout. Speak to your doctor or nurse, if you have questions about this. □ Complications of treatment can very occasionally be life-threatening and may result in death. The
☐ Changes to the lungs (due to inflammation, scarring or abnormal substances) causing shortness of breath, temperature is rare. If you have symptoms, inform your doctor or nurse.	risks are different for every individual. Potentially life-threatening complications include those listed on this form, but other exceedingly side effects may also be life-threatening.

To be retained in patient notes Prepared by Pharmacist: Alia Nizam Checked by Pharmacist: Reema Savjani Checked by Consultant: Adam Mead

Statement of health professional

Patient identifier/label

Any other risks and information:		
☐ I have discussed the intended benefit and risks of available alternative treatments (including no treatments)	·	
☐ I have discussed the side effects of the recommer straight away or in the future, and that there may I rare or have not yet been reported. Each patient n	be some side effects not listed because they are	
☐ I have discussed what the treatment is likely to invitiming of the treatment, blood and any additional t		
☐ I have explained to the patient, that they have the should contact the responsible consultant or team	•	
$\hfill \square$ I have discussed concerns of particular importance	e to the patient in regard to treatment	
(please write details here):		
Clinical management guideline/Protocol com	nnliant (nlease tick):	
	e document reason here:	
	, document readon nere:	
The following written information has	Health professional details:	
been provided:	Signed:	
☐ Information leaflet for Hydroxycarbamide	Date:	
24 hour alert card or SACT advice service contact details	Name (PRINT):	
SACT treatment record (cruk.org/treatment-		
record)	Job title:	
Other, please state:		
	1	
Statement of interpreter (where ap	propriate)	
Interpreter booking reference (if applicable):		
I have interpreted the information above to the patient believe they can understand.	t to the best of my ability and in a way in which I	
Signed:	Date:	
Name (PRINT):	Job title:	

To be retained in patient notes Prepared by Pharmacist: Alia Nizam Checked by Pharmacist: Reema Savjani Checked by Consultant: Adam Mead

Statement of patient

Patient identifier/label

your own copy of the form which describes the be	has been planned in advance, you should already have enefits and risks of the proposed treatment. If not, you er questions, do ask – we are here to help you. You have ng after you have signed this form.
☐ I have had enough time to consider my optio	ns and make a decision about treatment.
☐ I agree to the course of treatment described	on this form.
A witness should sign below if the patient is unab parental responsibility will be asked to sign for yo	ole to sign but has indicated their consent. A person with bung people under the age of 16 years.
Patient's signature:	
Name (PRINT):	Date:
Person with parental responsibility/witness' signa	iture:
Name (PRINT):	Date:
(health professional to complete when the patient attends for treatment, if the patient has signed the form in advance) On behalf of the team treating the patient, I have confirmed that the patient has no further questions and wishes the course of treatment/procedures to go ahead.	patients Contact details (if patient wishes to discuss options later):
	Contact your hospital team if you have any questions about cancer and its treatment.
Signed:	Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone 0808 800 4040, Monday to Friday, 9am to 5pm. Alternatively visit cruk.org for more information.
Date:	
Name (PRINT): Job title:	
Important notes: (tick if applicable)	
☐ See also advance decision to refuse treatment☐ Patient has withdrawn consent	These forms have been produced by Guy's and St. Thomas' NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT.
(ask patient to sign and date here) Signed:	The project is supported by
Date:	Cancer Research UK. This does not mean you are taking part in a clinical trial.

To be retained in patient notes Prepared by Pharmacist: Alia Nizam Checked by Pharmacist: Reema Savjani Checked by Consultant: Adam Mead

Guidance for health professionals

(to be read in conjunction with the hospital's consent policy)

Patient identifier/label

What a consent form is for

This form documents the patient's agreement to go ahead with the treatment you have proposed. It is not a legal waiver – if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient.

The law on consent

See the following publications for a comprehensive summary of the law on consent. Consent: Patients and doctors making decisions together, GMC 2020 (gmc-uk.org/guidance). Reference guide to consent for examination or treatment, Department of Health, 2nd edition 2009 (doh.gov.uk).

Who can give consent

Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. For young people, it is good practice to involve those with parental responsibility in the consent discussions, unless specifically asked not to. A person with parental responsibility must sign this form for a child or young person under the age of 16. Such patients should be given the opportunity to 'assent' to treatment if they wish. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual and ask an independent witness to confirm that the patient has given consent orally or non-verbally.

When NOT to use this form

If the patient lacks the capacity to give consent, you should use an alternative form available for this purpose (dependent on patient age). A patient lacks capacity if they have an impairment or disturbance of the brain, affecting the way their mind works. For example, if they cannot do one of the following:

- understand information about the decision to be made
- · retain that information in their mind
- use or weigh this information as a part of their decision making process, or

 communicate their decision (by talking, using sign language or any other means)

You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy.

Information

Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'significant, unavoidable or frequently occurring' risks. If patients make clear they have particular concerns about certain kinds of risk, you should ensure that they are informed about these risks, even if very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient's notes.

NHS Scotland

NHS Scotland staff should refer to Healthcare Improvement Scotland. Guidance on consent for SACT and local NHS Board guidance on consent aligned to the Scottish legal framework.

References

- Summary of Product Characteristics for individual drugs: medicines.org.uk/emc
- Cancer Research UK: cruk.org/aboutcancer/treatment/drugs
- Macmillan Cancer Support: macmillan.org.uk/cancer-information-andsupport/treatments-and-drugs
- 4. Guy's and St. Thomas' NHS Foundation Trust, Chemotherapy consent form